In addition, AMPK activation also suppresses mTOR signaling, which is important for premalignancy, initiation, and progression of HNSCC proved in past clinical trials [146,147,148,149,150] (Figure 5). This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.